Download PDF
Horm Metab Res 2011; 43(12): 844-853
DOI: 10.1055/s-0031-1291368
Review
© Georg Thieme Verlag KG Stuttgart · New York

Novel Therapeutic Agents for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors

M. E. Pavel
1   Charité Universitätsmedizin Berlin, Department of Gastroenterology & Hepatology, Endocrinology, Diabetes & Metabolic Diseases, Berlin, Germany
,
B. Wiedenmann
1   Charité Universitätsmedizin Berlin, Department of Gastroenterology & Hepatology, Endocrinology, Diabetes & Metabolic Diseases, Berlin, Germany
› Author Affiliations
Further Information

Publication History

received 01 August 2011

accepted 24 October 2011

Publication Date:
21 November 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Neuroendocrine tumors (NET) are frequently diagnosed late and not amenable to curative surgery due to metastatic disease to the liver and lymph nodes. The disease is complex and heterogeneous given the various functionalities, distinct tumor growth patterns, and tumor spread upon diagnosis. Established therapies include somatostatin analogues, alpha-interferon, systemic chemotherapy, and loco-regional therapies of the liver. The availability of novel agents and expression of targets, such as growth factor receptors, different subtypes of somatostatin receptors, and the mammalian target of rapamycin (mTOR) have led to the exploration of different classes of drugs and offer new treatment opportunities in neuroendocrine tumors. This review provides an overview on novel drugs, focus on the impact of recently approved drugs on the management of NET disease, and outline future perspectives.

Key words

targeted drugs - tyrosine kinase inhibitors - angiogenesis inhibitors - everolimus - sunitinib
 

  • References

  • 1 van Zwieten PA, Blauw GJ, van Brummelen P. Pathophysiological and pharmacotherapeutic aspects of serotonin and serotonergic drugs. Clin Physiol Biochem 1990; 8 (Suppl. 03) 1-18
    PubMedGoogle Scholar
  • 2 Vinik AI, Tsai ST, Moattari AR, Cheung P, Eckhauser FE, Cho K. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med 1986; 81: 23-40
    PubMedGoogle Scholar
  • 3 Wood SM, Kraenzlin ME, Adrian TE, Bloom SR. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue: symptomatic and peptide responses. Gut 1985; 26: 438-444
    CrossrefPubMedGoogle Scholar
  • 4 Öberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309: 129-133
    CrossrefPubMedGoogle Scholar
  • 5 Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-523
    CrossrefPubMedGoogle Scholar
  • 6 Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010; 102: 1106-1112
    CrossrefPubMedGoogle Scholar
  • 7 Fjallskog ML, Janson ET, Falkmer UG, Vatn MH, Oberg KE, Eriksson BK. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 2008; 88: 53-58
    CrossrefPubMedGoogle Scholar
  • 8 Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR. DOTATOC – a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24: 792-795
    PubMedGoogle Scholar
  • 9 Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev 2009; (2) CD007060
    PubMedGoogle Scholar
  • 10 Gurusamy KS, Pamecha V, Sharma D, Davidson BR. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev 2009; (1) CD007118
    PubMedGoogle Scholar
  • 11 Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G, Wildi S. and all other Frascati Consensus Conference participants . Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well Differentiated Jejunal-Ileal Tumor/Carcinoma. Neuroendocrinology 2008; 87: 8-19
    CrossrefPubMedGoogle Scholar
  • 12 Modlin IM, Pavel ME, Kidd M, Gustafsson B. Review Article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Alim Pharmacol Therap 2010; 31: 169-188
    PubMedGoogle Scholar
  • 13 Rinke A, Müller H, Schade-Brittinger C, Klose K, Barth P, Wied M, Mayer C, Aminossadati B, Pape U, Bläker M, Harder J, Arnold C, Gress T, Arnold R. PROMID study group . Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID Study Group. J Clin Oncol 2009; 28: 4656-4663
    PubMedGoogle Scholar
  • 14 Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, Ferdeghini M, Pederzoli P, Scarpa A, Falconi M. Butturini Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006; 13: 1213-1221
    CrossrefPubMedGoogle Scholar
  • 15 Faiss S, Pape UF, Bohmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B. and International Lanreotide and Interferon Alfa Study Group . Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-2696
    CrossrefPubMedGoogle Scholar
  • 16 Arnold R, Rinke A, Klose KJ, Müller HH, Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P, Moll R, Koller M, Unterhalt M, Hiddemann W, Schmidt-Lauber M, Pavel M, Arnold CN. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761-771
    CrossrefPubMedGoogle Scholar
  • 17 Pozsgai E, Schally AV, Halmos G, Rick F, Bellyei S. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. Horm Metab Res 2010; 42: 781-786
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumours: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23: 4897-4904
    CrossrefPubMedGoogle Scholar
  • 19 Dahan L, Bonnetain F, Rougier P, Raoul JL, Gamelin E, Etienne PL, Cadiot G, Mitry E, Smith D, Cvitkovic F, Coudert B, Ricard F, Bedenne L, Seitz JF. Fédération Francophone de Cancérologie Digestive (FFCD); Digestive Tumors Group of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) . Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Rel Cancer 2009; 16: 1351-1361
    CrossrefPubMedGoogle Scholar
  • 20 Joseph K, Stapp J, Reinecke J, Skamel HJ, Höffken H, Neuhaus C, Lenze H, Trautmann ME, Arnold R. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors. Horm Metab Res 1993; 27 (Suppl) 28-35
    PubMedGoogle Scholar
  • 21 Fjällskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson ET. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003; 20: 59-67
    CrossrefPubMedGoogle Scholar
  • 22 Welin S, Fjällskog ML, Saras J, Eriksson B, Janson ET. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 2006; 84: 42-48
    CrossrefPubMedGoogle Scholar
  • 23 Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993; 32: 107-114
    CrossrefPubMedGoogle Scholar
  • 24 Wulbrand U, Wied M, Zöfel P, Göke B, Arnold R, Fehmann H. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest 1998; 28: 1038-1049
    CrossrefPubMedGoogle Scholar
  • 25 von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000; 60: 4573-4581
    PubMedGoogle Scholar
  • 26 Nilsson O, Wangberg B, Theodorsson E, Skottner A, Ahlman H. Presence of IGF-I in human midgut carcinoid tumours – an autocrine regulator of carcinoid tumour growth?. Int J Cancer 1992; 51: 195-203
    CrossrefPubMedGoogle Scholar
  • 27 Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005; 18: 1329-1335
    CrossrefPubMedGoogle Scholar
  • 28 Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer 2011; 11: 573-587
    CrossrefPubMedGoogle Scholar
  • 29 Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Fléjou J, Degott C. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32: 133-138
    CrossrefPubMedGoogle Scholar
  • 30 Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309
    CrossrefPubMedGoogle Scholar
  • 31 Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K, Yao JC. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007; 109: 1478-1486
    CrossrefPubMedGoogle Scholar
  • 32 Pavel ME, Hassler G, Baum U, Hahn EG, Lohmann T, Schuppan D. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol (Oxf) 2005; 62: 434-443
    CrossrefPubMedGoogle Scholar
  • 33 Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, Caplin ME, Meyer T. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. Endocr Relat Cancer 2009; 16: 967-976
    CrossrefPubMedGoogle Scholar
  • 34 Detjen KM, Rieke S, Deters A, Schulz P, Rexin A, Vollmer S, Hauff P, Wiedenmann B, Pavel M, Scholz A. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res 2010; 16: 420-429
    CrossrefPubMedGoogle Scholar
  • 35 Figueroa-Vega N, Díaz A, Adrados M, Alvarez-Escolá C, Paniagua A, Aragonés J, Martín-Pérez E, Leskela S, Moreno-Otero R, González-Amaro R, Marazuela M. The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors. Endocr Relat Cancer 2010; 17: 897-908
    CrossrefPubMedGoogle Scholar
  • 36 Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM, Scarpa A. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28: 245-255
    CrossrefPubMedGoogle Scholar
  • 37 Kasajima A, Pavel M, Darb-Esfahani S, Noske A, Stenzinger A, Sasano H, Dietel M, Denkert C, Röcken C, Wiedenmann B, Weichert W. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2011; 18: 181-192
    CrossrefPubMedGoogle Scholar
  • 38 Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26: 1316-1323
    CrossrefPubMedGoogle Scholar
  • 39 Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia M, Lawrence C, Fuchs CS. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Proc Am Soc Clin Oncol 2006; 24 (18S) 4044
    PubMedGoogle Scholar
  • 40 Kunz P, Kuo T, Zahn JM, Kaiser HL, Norton JA, Visser BC, Longacre TA, Ford JM, Balise RR, Fisher GA. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol 2010; 28: 15s (suppl; abstr 4104)
    PubMedGoogle Scholar
  • 41 Venook AP, Ko AH, Tempero MA, Uy J, Weber T, Korn M, Bergsland EK. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol 2008; 26 (suppl; abstr 15545)
    PubMedGoogle Scholar
  • 42 Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol 2011; 68: 293-300
    CrossrefPubMedGoogle Scholar
  • 43 Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 2008; 61: 661-668
    CrossrefPubMedGoogle Scholar
  • 44 Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumor. J Clin Oncol 2006; 24: 3555-3561
    CrossrefPubMedGoogle Scholar
  • 45 Pavel ME, Bartel C, Heuck F, Neumann F, Tiling N, Pape UF, Plöckinger U, Wiedenmann B. Open-label, nonrandomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC). Proc Am Soc Clin Oncol 2008; 26: 14684
    PubMedGoogle Scholar
  • 46 Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-844 Review. Erratum in: Nat Rev Drug Discov 2007; 6: 126
    CrossrefPubMedGoogle Scholar
  • 47 Hobday T, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C. Sorafenib MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 2007; ASCO Annual Meeting Proceedings 2007; Part I. Vol 25, No. 18S (Suppl: 4504)
    PubMedGoogle Scholar
  • 48 Castellano DE, Capdevila J, Salazar R, Sastre J, Alonso V, Llanos M, Garcia-Carbonero R, Abad A, Sevilla I, Duran I. Spanish Neuroendocrine Tumor Group . (GETNE). Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). J Clin Oncol 2011; 29 (suppl; abstr 4113)
    PubMedGoogle Scholar
  • 49 Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337
    PubMedGoogle Scholar
  • 50 Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410
    CrossrefPubMedGoogle Scholar
  • 51 Raymond E, Dahan L, Raoul J-L, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513
    CrossrefPubMedGoogle Scholar
  • 52 Raymond E, Niccoli P, Raoul J, Bang Y, Borbath I, Lombard-Bohas C, Valle JW, Metrakos P, Smith D, Vinik A, Chen J, Hoersch D, Castellano DE, Kennecke HF, Picus J, Van Hazel G, Lu D, Chao RC, Patyna S, Van Cutsem E. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). J Clin Oncol 2011; 29 (suppl; abstr 4008)
    PubMedGoogle Scholar
  • 53 Phan AT, Yao JC, Fogelman DR, Hess KR, Ng CS, Bullock SA, Malinowski P, Regan E, Kulke M. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010; 28: 15s (suppl; abstr 4001)
    PubMedGoogle Scholar
  • 54 Hobday TJ, Holen K, Donehower R, Camoriano J, Kim G, Picus J, Philip P, Lloyd R, Mahoney M, Erlichman C. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. ASCO Annual Meeting Proceedings 2006; Part I. Vol 24, No. 18S (Suppl): 4043
    PubMedGoogle Scholar
  • 55 Reidy DL, Hollywood E, Segal M, Saltz L. A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). J Clin Oncol 2010; 28: 15s (suppl; abstr 4163)
    PubMedGoogle Scholar
  • 56 Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318
    CrossrefPubMedGoogle Scholar
  • 57 Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen St. S, Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O’Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumours after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69-76
    CrossrefPubMedGoogle Scholar
  • 58 Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523
    CrossrefPubMedGoogle Scholar
  • 59 Pavel M, Hainsworth JD, Baudin E, Peeters M, Hoersch D, Anthony L, Hoosen St. S, Peter J, Jehl V, Yao JC. A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus + octreotide LAR vs. placebo + octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). Ann Oncol 2010; 21 (Suppl. 08) viii1-viii12 LBA8
    PubMedGoogle Scholar
  • 60 Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146: 707-716
    Google Scholar
  • 61 Kvols L, Wiedenmann B, Oberg K, Glusman JE, O’dorisio TM, De Herder W, Gao B, Arnold R, Anthony L. The SOM230 Carcinoid Study Group. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (Suppl): 4082
    PubMedGoogle Scholar
  • 62 Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009; 360: 195-197
    CrossrefPubMedGoogle Scholar
  • 63 Ong GS, Henley DE, Hurley D, Turner JH, Claringbold PG, Fegan PG. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 2010; 162: 1001-1008
    CrossrefPubMedGoogle Scholar
  • 64 Fiebrich HB, Siemerink EJ, Brouwers AH, Links TP, Remkes WS, Hospers GA, de Vries EG. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist 2011; 16: 783-787
    CrossrefPubMedGoogle Scholar
  • 65 Ferrer-García JC, Tolosa-Torréns M, Hernando-Meliá C, Arribas-Palomar L, Sánchez-Juan C. Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma. Endocr Pract 2011; 17: e17-e20
    CrossrefPubMedGoogle Scholar
  • 66 De Vries E, Anthony LB, Sideris L, Chen L, Lebrec J, Tsuchihashi Z, Winkler RE, Yao JC, Öberg K. Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results. J Clin Oncol 2011; 29 (suppl; abstr 10624)
    PubMedGoogle Scholar
  • 67 Baudin E, Wolin EM, Castellano DE, Kaltsas G, Lebrec J, Tsuchihashi Z, Klimovsky J, Saletan S, Yao JC, Gross D. Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results. J Clin Oncol 2011; 29 (suppl; abstr 10527)
    PubMedGoogle Scholar
  • 68 Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-3074
    PubMedGoogle Scholar
  • 69 Zitzmann K, Rüden J, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer CJ. Compensatory activation of Akt in response to mTOR and Raf inhibitors – a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 2010; 295: 100-109
    CrossrefPubMedGoogle Scholar
  • 70 Chiu CW, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 2010; 28: 4425-4433
    CrossrefPubMedGoogle Scholar
  • 71 Grötzinger C. Tumour biology of gastroenteropancreatic neuroendocrine tumours. Neuroendocrinology 2004; 80 (Suppl. 01) 8-11
    CrossrefPubMedGoogle Scholar